Terns Pharmaceuticals’ $86 Million Common Stock Offering

Latham & Watkins LLP represented Terns Pharmaceuticals in the offering and Davis Polk advised the underwriters involved.Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing…

This content is for Standard 1 Year members only.
Login Join Now
Laura Testa

Author: Laura Testa

This content is for Standard 1 Year members only.
Login Join Now